Exelixis, Inc.
EXEL
Clasificación en acciones
#1383
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Precio por acción
$64.01
Última sincronización: 2026-10-20
Capitalización bursátil
$16.09B
Cambio (1 día)
2.11%
Cambio (1 año)
77.15%
País
US
Comercio Exelixis, Inc. (EXEL)
Categoría
Healthcare
Ratio P/E de Exelixis, Inc. (EXEL)
Ratio P/E al October 2026 TTM: 18.54
Según los últimos informes financieros y el precio de las acciones de Exelixis, Inc., el P/E actual (TTM) de la empresa es 18.54. Al final de 2025, la empresa tenía un P/E de 18.90.
Historial del ratio P/E de Exelixis, Inc. desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 18.54 | -1.92% |
| 2025 | 18.90 | -48.55% |
| 2023 | 36.74 | 29.84% |
| 2022 | 28.29 | 13.57% |
| 2021 | 24.91 | 55.37% |
| 2020 | 16.03 | 91.06% |
| 2018 | 8.39 | -85.50% |
| 2017 | 57.87 | -208.79% |
| 2016 | -53.19 | 5,005.52% |
| 2014 | -1.04 | -77.39% |
| 2013 | -4.61 | -5.78% |
| 2012 | -4.89 | -162.05% |
| 2011 | 7.88 | -181.69% |
| 2010 | -9.65 | 185.36% |
| 2009 | -3.38 | -66.78% |
| 2007 | -10.18 | 32.57% |
| 2006 | -7.68 | -12.69% |
| 2005 | -8.80 | 75.26% |
| 2004 | -5.02 | 3.18% |
| 2003 | -4.86 | -7.50% |
| 2002 | -5.26 | -51.55% |
| 2001 | -10.85 | 80.10% |
| 2000 | -6.03 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 28.78 | 55.26% |
US
|
|
| -28.36 | -252.97% |
US
|
|
| -24.57 | -232.52% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 63.61% |
NL
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.